RSS | Print | PDF | Email Page

Hatch Bill: Restore Hatch-Waxman Balance; Limit Generics’ Access to PTAB, PTAB Litigation Blog

July 2018


Visit the PTAB Litigation Blog.

Senator Orrin Hatch (R-Utah), the namesake and coauthor of the Hatch-Waxman Act, proposed (but has not yet introduced) an amendment titled the "Hatch-Waxman Integrity Act of 2018" during the Senate Judiciary Committee held on June 13, 2018. The purpose of the amendment, according to press release from the Senator’s Office, is to "ensure that Hatch-Waxman continues to operate as originally intended by protecting the ability of generic drug companies to develop low-cost drugs while at the same time ensuring brand-name companies have sufficient protections in place to recoup their investments."

Read the full article at ptablitigationblog.com.